Enphase Energy, Inc. to Join the NASDAQ-100 Index Beginning November 21, 2022

NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Enphase Energy, Inc. (Nasdaq: ENPH) will become a component of the NASDAQ-100 Index® (Nasdaq: NDX) and the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) prior to market open on Monday, November 21, 2022. Enphase Energy, Inc. will replace Okta, Inc. (Nasdaq: OKTA) in the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index. Okta, Inc. will also be removed from the NASDAQ-100 Technology Sector Index (Nasdaq: NDXT) and the NASDAQ-100 Technology Sector Market-Cap Weighted Index (Nasdaq: NDXTMC) prior to market open on Monday, November 21, 2022. Enphase Energy, Inc. will be considered for inclusion in the NASDAQ-100 Ex-Technology Index (Nasdaq: NDXX) at the next quarterly rebalancing.

For more information about the company, go to https://enphase.com/.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

NDAQG

You May Also Be Interested In

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
• How Minecraft's Creator Economy Keeps Growing After 17 Years
• Crypto News: Hyperliquid, TRUMP Memecoin, and MemeToro Shape the 2026 Altcoin Market